Le Lézard
Classified in: Health
Subjects: WOM, DEI

Gynov Commemorates the International Day of Action for Women's Health

The French Health Company Is Dedicated to Women's Health and Welcomes the Opportunity to Celebrate This Core Tenet of Its Mission

FORT LAUDERDALE, Fla., May 24, 2022 /PRNewswire/ -- May 28th is the International Day of Action for Women's Health. For over 30 years, the international community has used this day to celebrate women and fight for their health in different ways. Gynov is a French company that is doing its part to empower women in every area of their lives by creating dietary supplements that help to restore health and hope to those who are suffering from a variety of health conditions.

Women around the world currently face a large number of female-specific health concerns. Endometriosis, PCOS, post-menopausal disorders, recurrent vaginosis, and infertility are all common. Even so, many of these conditions suffer from a lack of therapeutic solutions.

Gynov has spent the last several years conducting innovative research in the area of women's health. The brand operates under a strict standard that brings together science and natural health in an attempt to rewrite the playbook and restore a sense of healthy positivity to women around the globe.

"We are shifting paradigms by combining the traditional scientific and medical rigor of conventional medicine with a more holistic view of bodily health," explains Gynov's co-founder and current CEO, Pierre-Yves Mousset, MD, "We don't just address symptoms of common conditions, like PCOS or Endometriosis. We help restore reproductive health on a fundamental level. This restores a sense of comprehensive health and control to women as they make health-related decisions that will impact their quality of life on a daily basis."

In pursuit of this end, Mousset's company has developed multiple groundbreaking supplements. Nausalys is one of these and is a dietary supplement that addresses nausea and vomiting during pregnancy. Gynositol is another, which focuses on many of the root causes of PCOS. These are safe supplements that utilize more natural solutions. For instance, Gynositol was created to relieve PCOS in an efficient and natural way by utilizing a formula that combines Myo-inositol and 5-MTHF ? two critical base elements for prolonged reproductive health.

Gynov's growing product line has been warmly received in over two dozen countries around the world to date. The brand is quickly becoming synonymous with women's health ? and it is proud to use the opportunity provided by the International Day of Action for Women's Health to reiterate its commitment to offering women health and hope.

About Gynov: Gynov was founded in France in 2016 by Pierre-Yves Mousset, MD. Gynov prides itself on using advanced scientific methods to develop high-quality, effective dietary supplements dedicated to women's health and beyond. These are created to support the efficacy of prescription drugs and help provide genuine solutions for female health concerns. Learn more at: gynov.com.

Please direct inquiries to:
Kelley Lake
(954) 673-5443
[email protected]


These press releases may also interest you

at 06:35
BiomX Inc. ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the dosing of the first two patients in the Company's Phase...

at 06:35
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company's ongoing natural history study of adrenomyeloneuropathy (AMN)...

at 06:30
BIOLASE, Inc. , the global leader in dental lasers, announced today that it has partnered with Project HOME, an organization that provides dental services to patients from their first birthday to adulthood. Project HOME's Healthcare Services is a...

at 06:05
Takeda (TSE:4502/NYSE:TAK) ("Takeda") and Arrowhead Pharmaceuticals Inc. today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with...

at 06:00
Today, IMPACT - the virtual-first care (V1C) initiative hosted by the Digital Medicine Society (DiMe) and the American Telemedicine Association (ATA) - launched the Effective V1C Care Transitions Toolkit, a robust set of resources that shows the...

at 06:00
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health...

News published on 24 may 2022 at 08:44 and distributed by: